Novel drug combination for cosmetic purposes
A technology of medicine and composition, applied in the field of pharmaceutical composition, to achieve the effects of low immunogenicity, long-lasting drug effect and promoting vascularization
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0052] In this example, the inventors screened the combination of mesenchymal stem cells from different sources with collagen or hyaluronic acid or calcium hydroxyapatite (microcrystalline porcelain) or polylactic acid or fat or platelet-rich plasma. Improve the effect of cell activity. In this embodiment, the cells to be improved are fibroblasts. Different sources of mesenchymal stem cells include: umbilical cord-derived, placental-derived, bone marrow-derived, periosteum-derived, fat-derived , of dental origin, etc. The inventors found that compared with other sources of mesenchymal stem cells, umbilical cord-derived mesenchymal stem cells belong to medical waste, have lower cell immunogenicity, and have certain versatility. The obtained cells are of high quality and large quantity , The purity is also higher. Furthermore, in subsequent experiments, the inventors selected a pharmaceutical composition comprising umbilical cord-derived mesenchymal stem cells and collagen or h...
Embodiment 2
[0054] In this example, the inventors observed and identified the morphology and phenotype of the selected umbilical cord mesenchymal stem cells. The results are described below:
[0055] The morphology of umbilical cord mesenchymal stem cells showed that the cells adhered to the wall, showed spindle shape, and grew in sheets. Specific forms such as figure 1 shown. Umbilical cord mesenchymal stem cells in figure 1 Under the growth state of umbilical cord mesenchymal stem cells, the proliferative ability of umbilical cord mesenchymal stem cells is strong, and the cytokines secreted including bFGF, VEGF, IGF, etc. stem cell.
[0056] The inventor identified by flow cytometry that the selected umbilical cord mesenchymal stem cells express CD90 (positive cell rate: 99%), CD105 (positive cell rate: 99%), CD73 (positive cell rate: 99%), and do not express HLA -DR, CD14, CD19, CD34 and CD45, the results are as figure 2 shown.
Embodiment 3
[0058] In this example, the inventors screened the amount of the selected umbilical cord-derived mesenchymal stem cells and hyaluronic acid.
[0059] The inventor has carried out the cell viability experiment of mesenchymal stem cells, and the experimental process is as follows:
[0060] 1. Digest umbilical cord mesenchymal stem cells: Digest a bottle of umbilical cord mesenchymal stem cells grown to 80% to 90% with trypsin, neutralize the medium, and centrifuge at 1200rpm for 5min;
[0061] 2. Resuspend cells: Discard the supernatant after centrifugation, and resuspend with umbilical cord mesenchymal stem cell medium;
[0062] 3. Inoculation of cells: The cells were inoculated according to the same volume (100 μl) (2000 mesenchymal stem cells per well), and each well was repeated 5 times, and the experiment was carried out for a total of 3 days, that is, each well had 15 replicates. The inoculated cells were then incubated at 37°C, 5% CO 2 Incubate overnight in an incubator...
PUM
| Property | Measurement | Unit |
|---|---|---|
| height | aaaaa | aaaaa |
| radius | aaaaa | aaaaa |
Abstract
Description
Claims
Application Information
Login to View More